Novugen (Kinase Inhibitor Medication for Cancer) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Novugen (Kinase Inhibitor Medication for Cancer) General Information

Description

A medication for cancer treatment based in Shah Alam, Malaysia.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Shah Alam, Selangor 40150
  • Malaysia
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Corporate Office
  • Shah Alam, Selangor 40150
  • Malaysia

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Novugen (Kinase Inhibitor Medication for Cancer) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Novugen (Kinase Inhibitor Medication for Cancer)‘s full profile, request access.

Request a free trial

Novugen (Kinase Inhibitor Medication for Cancer) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Novugen (Kinase Inhibitor Medication for Cancer)‘s full profile, request access.

Request a free trial

Novugen (Kinase Inhibitor Medication for Cancer) FAQs

  • Where is Novugen (Kinase Inhibitor Medication for Cancer) headquartered?

    Novugen (Kinase Inhibitor Medication for Cancer) is headquartered in Shah Alam, Malaysia.

  • What industry is Novugen (Kinase Inhibitor Medication for Cancer) in?

    Novugen (Kinase Inhibitor Medication for Cancer)’s primary industry is Buildings and Property.

  • Is Novugen (Kinase Inhibitor Medication for Cancer) a private or public company?

    Novugen (Kinase Inhibitor Medication for Cancer) is a Private company.

  • What is Novugen (Kinase Inhibitor Medication for Cancer)’s current revenue?

    The current revenue for Novugen (Kinase Inhibitor Medication for Cancer) is .

  • Who are Novugen (Kinase Inhibitor Medication for Cancer)’s investors?

    Novugen has invested in Novugen (Kinase Inhibitor Medication for Cancer).

  • When was Novugen (Kinase Inhibitor Medication for Cancer) acquired?

    Novugen (Kinase Inhibitor Medication for Cancer) was acquired on 17-Apr-2025.

  • Who acquired Novugen (Kinase Inhibitor Medication for Cancer)?

    Novugen (Kinase Inhibitor Medication for Cancer) was acquired by Hikma Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process